Details

Autor(en) / Beteiligte

• Pfeffer, Marc A
• McMurray, John J.V
• Velazquez, Eric J
• Rouleau, Jean-Lucien
• Køber, Lars
• Maggioni, Aldo P
• Solomon, Scott D
• Swedberg, Karl
• Van de Werf, Frans
• White, Harvey
• Leimberger, Jeffrey D
• Henis, Marc
• Edwards, Susan
• Zelenkofske, Steven
• Sellers, Mary Ann
• Califf, Robert M

Titel

Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both

Ist Teil von

• The New England journal of medicine, 2003-11, Vol.349 (20), p.1893-1906

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2003

Quelle

MEDLINE

Beschreibungen/Notizen

• It is known that the angiotensin-converting–enzyme inhibitor captopril is beneficial in patients with myocardial infarction complicated by left ventricular dysfunction or heart failure. This study compared captopril with valsartan, an angiotensin-receptor blocker, and the combination of the two drugs in such patients. Mortality was the same in the three groups, but there were more side effects with the combination therapy. In patients with heart failure, valsartan is an alternative. Multiple randomized, placebo-controlled trials involving a total of more than 100,000 patients have demonstrated that angiotensin-converting–enzyme (ACE) inhibitors reduce the risk of death as well as the risk of major nonfatal cardiovascular events after myocardial infarction. 1 – 8 The greatest relative and absolute benefits have been obtained with long-term ACE-inhibitor therapy in high-risk patients — specifically, in those with left ventricular dysfunction, signs or symptoms of heart failure, or both. 9 , 10 Angiotensin-receptor blockers offer an alternative approach to the inhibition of the renin–angiotensin system. 11 The identification of a functioning chymase in humans that is capable of generating angiotensin II independently of . . .